|
[1]
|
Esposito, K., Capuano, A. and Giugliano, D. (2014) Metabolic Syndrome and Cancer: Holistic or Reductionist? Endocrine, 45, 362-364. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Brooks, N.A., Kokorovic, A., Xiao, L., Matulay, J.T., Li, R., Ranasinghe, W.K., et al. (2020) The Obesity Paradox: Defining the Impact of Body Mass Index and Diabetes Mellitus for Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. BJU International, 128, 65-71. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Turner, R.M., Kwok, C.S., Chen-Turner, C., Maduakor, C.A., Singh, S. and Loke, Y.K. (2014) Thiazolidinediones and Associated Risk of Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal of Clinical Pharmacology, 78, 258-273. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Newton, C.C., Gapstur, S.M., Campbell, P.T. and Jacobs, E.J. (2013) Type 2 Diabetes Mellitus, Insulin-Use and Risk of Bladder Cancer in a Large Cohort Study. International Journal of Cancer, 132, 2186-2191. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Malats, N. and Real, F.X. (2015) Epidemiology of Bladder Cancer. Hematology/Oncology Clinics of North America, 29, 177-189. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Tseng, C.H. (2012) Pioglitazone and Bladder Cancer in Human Studies: Is It Diabetes Itself, Diabetes Drugs, Flawed Analyses or Different Ethnicities? Journal of the Formosan Medical Association, 111, 123-131. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Tang, H., Shi, W., Fu, S., Wang, T., Zhai, S., Song, Y., et al. (2018) Pioglitazone and Bladder Cancer Risk: A Systematic Review and Meta-Analysis. Cancer Medicine, 7, 1070-1080. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Tai, Y.S., Chen, C.H., Huang, C.Y., Tai, H.-C., Wang, S.-M., and Pu, Y.-S. (2015) Diabetes Mellitus with Poor Glycemic Control Increases Bladder Cancer Recurrence Risk in Patients with Upper Urinary Tract Urothelial Carcinoma. Diabetes/Metabolism Research and Reviews, 31, 307-314. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Grossman, E., Messerli, F.H., Boyko, V. and Goldbourt, U. (2002) Is There an Association between Hypertension and Cancer Mortality? American Journal of Medicine, 112, 479-486. [Google Scholar] [CrossRef]
|
|
[10]
|
Larsson, S.C., Andersson, S.O., Ohansson, J.E. and Wolk, A. (2008) Diabetes Mellitus, Body Size and Bladder Cancer Risk in a Prospective Study of Swedish Men. European Journal of Cancer, 44, 2655-2660. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Huang, W.L., Huang, K.H., Huang, C.Y., Pu, Y.-S., Chang, H.-C. and Chow, P.-M. (2020) Effect of Diabetes Mellitus and Glycemic Control on the Prognosis of Non-Muscle Invasive Bladder Cancer: A Retrospective Study. BMC Urology, 20, Article No. 117. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Chestnut, C., Smelser, W., Dum, T., Bechtel, M., Hand, L., Michel, C., et al. (2020) Glycemic Impact of a Diet and Lifestyle Intervention on Diabetics and Prediabetics during Treatment for Non-Muscle Invasive Bladder Cancer. Nutrition and Cancer, 72, 1219-1224. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Jiang, X., Castelao, J.E., Yuan, J.M., Groshen, S., Stern, M.C., Conti, D.V., et al. (2010) Hypertension, Diuretics and Antihypertensives in Relation to Bladder Cancer. Carcinogenesis, 31, 1964-1971. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Yu, H., Hemminki, O., Försti, A., Sundquist, K. and Hemminki, K. (2018) Familial Urinary Bladder Cancer with Other Cancers. European Urology Oncology, 1, 461-466. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Friedenreich, C.M., Ryder-Burbidge, C. and Mcneil, J. (2021) Physical Activity, Obesity and Sedentary Behavior in Cancer Etiology: Epidemiologic Evidence and Biologic Mechanisms. Molecular Oncology, 15, 790-800. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Amara, C.S., Vantaku, V., Lotan, Y. and Putluri, N. (2019) Recent Advances in the Metabolomic Study of Bladder Cancer. Expert Review of Proteomics, 16, 315-324. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Wigner, P., Grębowski, R., Bijak, M., Saluk-Bijak, J. and Szemraj, J. (2021) The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development. International Journal of Molecular Sciences, 22, Article No. 4483. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Xie, Y., Xu, P., Wang, M., Zheng, Y., Tian, T., Yang, S., et al. (2020) Antihypertensive Medications Are Associated with the Risk of Kidney and Bladder Cancer: A Systematic Review and Meta-Analysis. Aging, 12, 1545-1562. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Tuccori, M., Filion, K.B., Yin, H., Yu, O.H., Platt, R.W. and Azoulay, L. (2016) Pioglitazone Use and Risk of Bladder Cancer: Population Based Cohort Study. BMJ, 352, Article No. i1541. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Wang, Q., Zhang, T., Wu, J., Wen, J., Tao, D., Wan, T., et al. (2019) Prognosis and Risk Factors of Patients with Upper Urinary Tract Urothelial Carcinoma and Postoperative Recurrence of Bladder Cancer in Central China. BMC Urology, 19, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lewis, J.D., Habel, L., Quesenberry, C., Mamtani, R., Peng, T., Bilker, W.B., et al. (2014) Proteinuria Testing among Patients with Diabetes Mellitus Is Associated with Bladder Cancer Diagnosis: Potential for Unmeasured Confounding in Studies of Pioglitazone and Bladder Cancer. Pharmacoepidemiology and Drug Safety, 23, 636-645. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Zhao, L., Tian, X., Duan, X., Ye, Y., Sun, M. and Huang, J. (2017) Association of Body Mass Index with Bladder Cancer Risk: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Oncotarget, 8, 33990-34000. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Xu, X., Zhou, L., Miao, R., Chen, W., Zhou, Y., Pang, Q., et al. (2016) Association of Cancer Mortality with Postdiagnosis Overweight and Obesity Using Body Mass Index. Oncotarget, 7, 5023-5029. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Choi, J.B., Kim, J.H., Hong, S., Han, K.-D. and Ha, U.-S. (2019) Association of Body Mass Index with Bladder Cancer Risk in Men Depends on Abdominal Obesity. World Journal of Urology, 37, 2393-2400. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Choi, J.B., Lee, E.J., Han, K., Hong, S.-H. and Ha, U.-S. (2018) Estimating the Impact of Body Mass Index on Bladder Cancer Risk: Stratification by Smoking Status. Scientific Reports, 8, Article No. 947. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Lin, Y., Wang, Y., Wu, Q., Jin, H., Ma, G., Liu, H., et al. (2018) Association between Obesity and Bladder Cancer Recurrence: A Meta-Analysis. Clinica Chimica Acta, 480, 41-46. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Noguchi, J.L., Liss, M.A. and Parsons, J.K. (2015) Obesity, Physical Activity and Bladder Cancer. Current Urology Reports, 16, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Shi, J., Zhao, L., Gao, Y., Niu, M., Yan, M., Chen, Y., et al. (2021) Associating the Risk of Three Urinary Cancers with Obesity and Overweight: An Overview with Evidence Mapping of Systematic Reviews. Systematic Reviews, 10, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Chu, K.F., Rotker, K. and Ellsworth, P. (2013) The Impact of Obesity on Benign and Malignant Urologic Conditions. Postgraduate Medicine, 125, 53-69. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Dabi, Y., Rouscoff, Y., Anract, J., Delongchamps, N.B., Sibony, M., Saighi, D., et al. (2017) Impact of Body Mass Index on the Oncological Outcomes of Patients Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer. World Journal of Urology, 35, 229-235. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Jee, S.H., Yun, J.E., Park, E.J., Cho, E.R., Park, I.S., Sull, J.W., Ohrr, H. and Samet, J.M. (2008) Body Mass Index and Cancer Risk in Korean Men and Women. The International Journal of Cancer, 123, 1892-1896. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Ahn, J.H., Jung, S.I., Yim, S.U., Kim, S.W., Hwang, E.C. and Kwon, D.D. (2016) Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. Journal of Korean Medical Science, 31, 1464-1471. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Cantiello, F., Cicione, A., Salonia, A., Autorino, R., De Nunzio, C., Briganti, A., et al. (2015) Association between Metabolic Syndrome, Obesity, Diabetes Mellitus and Oncological Outcomes of Bladder Cancer: A Systematic Review. International Journal of Urology, 22, 22-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Cresswell, J. (2013) Diabetes Mellitus and Non-Muscle-Invasive Bladder Cancer: Not Just a Coincidence? BJU International, 112, 1055-1056. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Parra-Soto, S., Cowley, E.S., Rezende, L.F.M., Ferreccio, C., Mathers, J.C., Pell, J.P., et al. (2021) Associations of Six Adiposity-Related Markers with Incidence and Mortality from 24 Cancers—Findings from the UK Biobank Prospective Cohort Study. BMC Medicine, 19, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Batty, G.D., Shipley, M.J., Jarrett, R.J., Breeze, E., Marmot, M.G. and Smith, G.D. (2005) Obesity and Overweight in Relation to Organ-Specific Cancer Mortality in London (UK): Findings from the Original Whitehall Study. International Journal of Obesity, 29, 1267-1274. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Sørensen, K.K., Jensen, B.W., Thomas, P.E., Madsen, K., Eriksson, F., Aarestrup, J., et al. (2020) Early Life Body Size and Its Associations with Adult Bladder Cancer. Annals of Human Biology, 47, 166-172. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Huynh, M.J., Wang, Y., Chang, S.L., Tully, K.H., Chung, B.I., Wright, J.L., et al. (2020) The Cost of Obesity in Radical Cystectomy. Urologic Oncology: Seminars and Original Investigations, 38, 932-939. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Rezaei, F., Tabatabaee, H., Rahmanian, V., Mirahmadizadeh, A. and Hassanipour, S. (2019) The Correlation between Bladder Cancer and Obesity, Overweight, Physical Inactivity, and Tobacco Use: An Ecological Study in Asian Countries. Annals of Global Health, 85, Article No. 102. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Sanchez, A., Kissel, S., Coletta, A., Scott, J. and Furberg, H. (2020) Impact of Body Size and Body Composition on Bladder Cancer Outcomes: Risk Stratification and Opportunity for Novel Interventions. Urologic Oncology: Seminars and Original Investigations, 38, 713-718. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Wade, K.H., Carslake, D., Sattar, N., Smith, Davey, G. and Timpson, N.J. (2018) BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization. Obesity, 26, 1796-1806. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Aarestrup, J., Bjerregaard, L.G., Meyle, K.D., Pedersen, D.C., Gjærde, L.K., Jensen, B.W., et al. (2020) Birthweight, Childhood Overweight, Height and Growth and Adult Cancer Risks: A Review of Studies Using the Copenhagen School Health Records Register. International Journal of Obesity, 44, 1546-1560. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
肖荣, 于佳, 徐建华, 杨元强. 膀胱癌分期分级与代谢综合征及组分的相关性研究[J]. 临床医药文献电子杂志, 2019, 6(39): 17-18.
|
|
[44]
|
De Ridder, J., Julián-Almárcegui, C., Mullee, A., Rinaldi, S., Van Herck, K., Vicente-Rodríguez, G., et al. (2016) Comparison of Anthropometric Measurements of Adiposity in Relation to Cancer Risk: A Systematic Review of Prospective Studies. Cancer Causes & Control, 27, 291-300. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Fang, H., Yao, B., Yan, Y., Xu, H., Liu, Y., Tang, H., et al. (2013) Diabetes Mellitus Increases the Risk of Bladder Cancer: An Updated Meta-Analysis of Observational Studies. Diabetes Technology & Therapeutics, 15, 914-922. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Gild, P., Ehdaie, B. and Kluth, L.A. (2017) Effect of Obesity on Bladder Cancer and Renal Cell Carcinoma Incidence and Survival. Current Opinion in Urology, 27, 409-414. [Google Scholar] [CrossRef]
|
|
[47]
|
Teleka, S., Jochems, S.H.J., Häggström, C., Wood, A.M., Järvholm, B., Orho-Melander, M., et al. (2021) Association between Blood Pressure and BMI with Bladder Cancer Risk and Mortality in 340,000 Men in Three Swedish Cohorts. Cancer Medicine, 10, 1431-1438. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Davidson, M.B. (2016) Pioglitazone (Actos) and Bladder Cancer: Legal System Triumphs over the Evidence. J Diabetes Complications, 30, 981-985. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Zhu, Z., Zhang, X., Shen, Z., Zhong, S., Wang, X., Lu, Y., et al. (2013) Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies. PLoS ONE, 8, e56662. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Wang, M., Yang, Y. and Liao, Z. (2020) Diabetes and Cancer: Epidemiological and Biological Links. World Journal of Diabetes, 11, 227-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Dąbrowski, M. (2021) Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. International Journal of Molecular Sciences, 22, Article No. 1680. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Lundberg, E., Hagberg, O., Jahnson, S. and Ljungberg, B. (2019) Association between Occurrence of Urinary Bladder Cancer and Treatment with Statin Medication. Turkish Journal of Urology, 45, 97-102. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Goossens, M.E., Zeegers, M.P., Bazelier, M.T., De Bruin, M.L., Buntinx, F. and de Vries, F. (2015) Risk of Bladder Cancer in Patients with Diabetes: A Retrospective Cohort Study. BMJ Open, 5, Article No. e7470. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Gupta, S., Gupta, K., Ravi, R., Mehta, V., Banerjee, S., Joshi, S., et al. (2015) Pioglitazone and the Risk of Bladder Cancer: An Indian Retrospective Cohort Study. Indian Journal of Endocrinology and Metabolism, 19, 639-643. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Han, E., Jang, S.Y., Kim, G., Lee, Y.-H., Choe, E.Y., Nam, C., et al. (2016) Rosiglitazone Use and the Risk of Bladder Cancer in Patients with Type 2 Diabetes. Medicine, 95, Article No. e2786. [Google Scholar] [CrossRef]
|
|
[56]
|
Xu, Y., Huo, R., Chen, X. and Yu, X. (2017) Diabetes Mellitus and the Risk of Bladder Cancer: A PRISMA-Com- pliant Meta-Analysis of Cohort Studies. Medicine, 96, Article No. e8588. [Google Scholar] [CrossRef]
|
|
[57]
|
Yang, S.L., Wang, J.J., Chen, M., Xu, L., Li, N., Luo, Y.-L., et al. (2018) Pioglitazone Use and Risk of Bladder Cancer: An in Vitro Study. International Journal of Medical Sciences, 15, 228-237. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Lin, C., Travis, R.C., Appleby, P.N., Tipper, S., Weiderpass, E., Chang-Claude, J., et al. (2018) Pre-Diagnostic Circulating Insulin-Like Growth Factor-I and Bladder Cancer Risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 143, 2351-2358. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Turati, F., Polesel, J., Di Maso, M., Montella, M., Libra, M., Grimaldi, M., et al. (2015) Diabetes Mellitus and the Risk of Bladder Cancer: An Italian Case-Control Study. British Journal of Cancer, 113, 127-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Gislefoss, R.E., Stenehjem, J.S., Hektoen, H.H., Andreassen, B.K., Langseth, H., Axcrona K., et al. (2018) Vitamin D, Obesity and Leptin in Relation to Bladder Cancer Incidence and Survival: Prospective Protocol Study. BMJ Open, 8, Article No. e019309. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Nagano, T., Otoshi, T., Hazama, D., Kiriu, T., Umezawa, K., Katsurada, N., et al. (2019) Novel Cancer Therapy Targeting Microbiome. OncoTargets and Therapy, 12, 3619-3624. [Google Scholar] [CrossRef]
|
|
[62]
|
Ferwana, M., Firwana, B., Hasan, R., Al-Mallah, M.H., Kim, S., Montori, V.M., et al. (2013) Pioglitazone and Risk of Bladder Cancer: A Meta-Analysis of Controlled Studies. Diabetic Medicine, 30, 1026-1032. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Evers, J., Grotenhuis, A.J., Aben, K., Kiemeney, L.A. and Vrieling, A. (2020) No Clear Associations of Adult BMI and Diabetes Mellitus with Non-Muscle Invasive Bladder Cancer Recurrence and Progression. PLoS ONE, 15, e229384. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Larsson, S.C., Orsini, N., Brismar, K. and Wolk, A. (2006) Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis. Diabetologia, 49, 2819-2823. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Hu, J., Chen, J.B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., et al. (2018) Association of Metformin Intake with Bladder Cancer Risk and Oncologic Outcomes in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis. Medicine, 97, Article No. e11596. [Google Scholar] [CrossRef]
|
|
[66]
|
Lewis, J.D., Habel, L.A., Quesenberry, C.P., Strom, B.L., Peng, T., Hedderson, M.M., et al. (2015) Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons with Diabetes. JAMA, 314, 265-277. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Levin, D., Bell, S., Sund, R., Hartikainen, S.A., Tuomilehto, J., Pukkala, E., et al. (2015) Pioglitazone and Bladder Cancer Risk: A Multipopulation Pooled, Cumulative Exposure Analysis. Diabetologia, 58, 493-504. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Li, Z., Sun, M., Wang, F., Shi, J. and Wang, K. (2017) Association between Pioglitazone Use and the Risk of Bladder Cancer among Subjects with Diabetes Mellitus: A Dose-Response Meta-Analysis. International Journal of Clinical Pharmacology and Therapeutics, 55, 210-219. [Google Scholar] [CrossRef]
|
|
[69]
|
Mackenzie, T., Zens, M.S., Ferrara, A., Schned, A. and Karagas, M.R. (2011) Diabetes and Risk of Bladder Cancer: Evidence from a Case-Control Study in New England. Cancer, 117, 1552-1556. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Liu, Y., Wu, X., Wang, G., Hu, S., Zhang, Y. and Zhao, S. (2019) CALD1, CNN1, and TAGLN Identified as Potential Prognostic Molecular Markers of Bladder Cancer by Bioinformatics Analysis. Medicine, 98, e13847. [Google Scholar] [CrossRef]
|
|
[71]
|
Ng, Y., Husain, I. and Waterfall, N. (2003) Diabetes Mellitus and Bladder Cancer—An Epidemiological Relationship? Pathology Oncology Research, 9, Article No. 30. [Google Scholar] [CrossRef]
|
|
[72]
|
Zhu, Z., Wang, X., Shen, Z., Lu, Y., Zhong, S. and Chen, X. (2013) Risk of Bladder Cancer in Patients with Diabetes Mellitus: An Updated Meta-Analysis of 36 Observational Studies. BMC Cancer, 13, Article No. 310. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Yang, X.Q., Xu, C., Sun, Y. and Han, R.-F. (2013) Diabetes Mellitus Increases the Risk of Bladder Cancer: An Updated Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 14, 2583-2589. [Google Scholar] [CrossRef]
|
|
[74]
|
Xu, X., Wu, J., Mao, Y., Zhu, Y., Hu, Z., Xu, X., et al. (2013) Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies. PLoS ONE, 8, e58079. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Wei, L., Macdonald, T.M. and Mackenzie, I.S. (2013) Pioglitazone and Bladder Cancer: A Propensity Score Matched Cohort Study. British Journal of Clinical Pharmacology, 75, 254-259. [Google Scholar] [CrossRef] [PubMed]
|
|
[76]
|
Warren, H., Raison, N. and Dasgupta, P. (2016) Pioglitazone and Bladder Cancer. BJU International, 118, 16-17. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Wang, Z., Ong, W., Tong, S., Sng, J.-H., Mani Lata, R., Mahendran, R., et al. (2020) Beyond Diabetes Mellitus: Role of Metformin in Non-Muscle Invasive Bladder Cancer. Singapore Medical Journal. [Google Scholar] [CrossRef] [PubMed]
|